A medical condition called sleep disorder, commonly referred to as insomnia, is characterized by a patient's struggle to initiate or sustain sleep. This ailment disrupts various aspects of mental, physical, social, and emotional well-being. Additionally, the emergence of at-home sleep test kits and the utilization of wearable monitoring devices and continuous positive airway pressure (CPAP) therapy create new prospects within the market.

Global Sleep Disorder market was valued US $22.5 Bn in 2022 and expected to reach US $70.8 Bn by 2032, growing at a CAGR of 12% during the forecast period 2023-2032.

One of the primary drivers of demand for diagnostic and therapeutic equipment is the increasing number of patients dealing with sleep apnea and related comorbidities. These devices are sought after for their reliability and user-friendly design, making it easier for patients to conduct sleep tests. According to estimates by the American Sleep Association, there are between 50 and 70 million individuals in the United States grappling with sleep disorders. These conditions often co-occur with issues like anxiety, depression, and post-traumatic stress disorder (PTSD). This elevated prevalence is also linked to the growing adoption of a sedentary lifestyle, which is expected to boost the market's size.

COVID -19 Impact on Sleep Disorder Market

The Sleep Disorder market underwent substantial changes due to the COVID-19 pandemic, presenting both challenges and opportunities. The pandemic has caused a surge in sleep-related problems for many individuals. Factors such as heightened stress, anxiety, and disruptions to daily routines have led to more people experiencing insomnia, sleep disturbances, and other sleep disorders.

As reported in a March 2022 NCBI article, Europe witnessed a considerable incidence of new-onset COVID-19-related insomnia, reaching as high as 13.6%. Concurrently, the prevalence of clinical insomnia in the region stood at 18.6% in 2021. Additionally, a separate study published in September 2020 by Springer indicated that individuals with obstructive sleep apnea faced a significantly elevated risk of COVID-19 infection, approximately eight times higher than a similar-aged population receiving care in a diverse healthcare system encompassing various racial and socio-economic backgrounds. Furthermore, obstructive sleep apnea was associated with an increased likelihood of hospitalization among COVID-19 patients and nearly doubled the risk of developing respiratory failure. Consequently, the impact of COVID-19 infections on the market's growth trajectory was substantial. Nevertheless, the market is anticipated to experience growth over the next five years due to the growing adoption of sleep disorder treatments.

Telemedicine became a more prominent mode of healthcare delivery during the pandemic. Healthcare providers started offering virtual consultations, including for sleep disorders. Remote monitoring devices for sleep apnea and other conditions gained traction as well. The pandemic's focus on respiratory health and respiratory devices has spurred research and development in the field of sleep apnea and related disorders. Innovations in ventilator technology have potential applications in sleep therapy. Access to sleep disorder treatments and medications may have been disrupted during lockdowns and supply chain disruptions. Patients may have experienced challenges in obtaining their prescribed treatments.

Factors Driving the Sleep Disorder Market

Drivers

Increasing awareness related to sleep disorders among the patient population.

Sleep disorders are common worldwide. According to the American Sleep Association, 50 to 70 million adults in the United States alone have a sleep disorder.

The prevalence of sleep disorders can vary based on factors such as geographic location, age groups, and the specific type of sleep disorder. Insomnia is one of the most common sleep disorders approximately 30% of the general population reports symptoms of insomnia. Narcolepsy is less common than insomnia or OSA. It affects about 1 in 2,000 people in the United States. Onset typically occurs in adolescence or early adulthood. Sleep disorders are often comorbid with mental health conditions such as depression and anxiety. 50-80% of individuals with depression experience sleep disturbances. The awareness and diagnosis of sleep disorders have been increasing in recent years, which may lead to higher reported prevalence rates.

Overall, sleep disorders are a significant public health concern due to their widespread prevalence and potential impact on individuals' physical and mental well-being. Early detection and appropriate management are essential for improving the quality of life for those affected by sleep disorders.

Increasing awareness related to sleep disorders among the patient population is crucial for several reasons such as early detection allows for prompt diagnosis and treatment, which can lead to better outcomes and an improved quality of life. Many sleep disorders, such as sleep apnea, are associated with various health risks, including cardiovascular problems, diabetes, and obesity. Raising awareness about these risks can motivate individuals to address their sleep issues and reduce the likelihood of developing these comorbid conditions. As awareness grows, healthcare providers are more likely to prioritize the evaluation and treatment of sleep disorders during medical visits. This can lead to more accessible and timely care for individuals seeking help. Raising awareness about sleep disorders can have workplace implications. Employees who are well-rested and free from sleep disorders are more likely to be productive and, in certain industries like transportation, contribute to enhanced safety.

Sleep disorders can affect not only the individual but also their family members and communities. Increased awareness can lead to better support systems and resources for those affected by sleep disorders. A heightened focus on sleep disorders often results in increased research efforts and innovations in diagnostics and treatments. This can lead to advancements in the field and improved options for individuals with sleep disorders.

Awareness campaigns, educational initiatives, and community outreach efforts are essential tools for increasing awareness related to sleep disorders. These efforts empower individuals to take charge of their sleep health, seek timely medical intervention, and lead healthier, more fulfilling lives.

Challenges

Lower Diagnosis Rate

The lower diagnosis rate of sleep disorders presents a significant challenge in the healthcare system. Many individuals may not be aware of the signs and symptoms of sleep disorders or underestimate their significance. This lack of awareness leads to a delay in seeking medical evaluation and diagnosis. There can be a social stigma associated with sleep disorders, particularly with conditions like insomnia or snoring. People may feel embarrassed to discuss their sleep problems with healthcare providers or family members, leading to underreporting. Some symptoms of sleep disorders, such as fatigue, mood disturbances, and difficulty concentrating, can overlap with other medical or psychological conditions. This can result in sleep disorders being misdiagnosed or overlooked. In some regions or communities, access to healthcare services, including sleep clinics and specialists, may be limited. People in underserved areas may face barriers to diagnosis.

The diagnosis of certain sleep disorders, such as sleep apnea, often involves conducting sleep studies in specialized facilities. This can be seen as a cumbersome and time-consuming process, discouraging some individuals from pursuing diagnosis. Healthcare providers may not routinely screen for sleep disorders during general medical check-ups, missing opportunities for early detection. Some individuals may attempt to self-medicate their sleep problems with over-the-counter sleep aids or other substances, rather than seeking professional help. This can further delay diagnosis.

Sleep Disorder Market Segmentation 

By Disorder

The segmentation analysis of disorder segment, the market is segmented into sleep apnea, restless legs syndrome, insomnia, narcolepsy, circadian disorders, and others segment.

Throughout the forecast period, it is expected that insomnia will maintain its dominant position in the sleep disorders treatment market. This is primarily due to the escalating prevalence of insomnia, a condition characterized by severe and uncontrollable daytime sleepiness, as well as sudden muscle tone loss. In 2021, the National Institutes of Health (NIH) estimated that 30% of the general population reported experiencing disruptions in their sleep, with 10% exhibiting symptoms of daytime functional impairment consistent with insomnia diagnosis. Furthermore, a 2021 article published by the National Centre for Biotechnology Information (NCBI) indicated that more than 10% of the European population consistently experienced chronic insomnia.

The increasing number of drug approvals for insomnia is also anticipated to contribute to the growth of this segment. For instance, in June 2022, Daridorexant, a medication designed for the treatment of insomnia, received approval in Europe to address sleep-related disorders and related conditions. Additionally, in July 2021, Esai Co. Ltd introduced DAYVIGO, an orexin receptor antagonist developed in-house, specifically targeting insomnia in adults characterized by difficulties with sleep onset.

The growth of this segment is further propelled by the rising awareness campaigns dedicated to the disorder and the available treatment options, which promote early diagnosis and increased healthcare spending. For example, in January 2022, the National Sleep Foundation launched Sleep Awareness Week, aiming to underscore the crucial connection between sleep and overall health.

By Drug

The segmentation analysis of drug segment, the market is segmented into benzodiazepines, nonbenzodiazepines, and antidepressants. Benzodiazepines are a class of psychoactive drugs that have a central nervous system depressant effect. They are commonly prescribed for various medical conditions, primarily related to the treatment of anxiety, insomnia, and seizures. These drugs are prescribed for a range of medical conditions, including anxiety disorders, panic disorders, insomnia, muscle spasms, and certain seizure disorders. They are often used on a short-term basis due to the risk of tolerance, dependence, and potential withdrawal symptoms.

By Route Of Administration

The segmentation analysis of route of administration segment, the market is segmented into oral, parenteral, and others. Oral segment accounted for the largest market share which is anticipated to witness highest growth rate during the forecast period.

By End-use

The segmentation analysis of end-use segment, the market is segmented into home care settings & individuals, sleep laboratories, and hospitals. Sleep disorder diagnosis and treatment often occur in hospitals, especially in sleep clinics or specialized units. Hospitals may offer a range of services, including polysomnography (sleep studies) and consultation with sleep specialists. Primary care physicians often play a key role in identifying and managing sleep disorders. Patients may initially seek help from family doctors or general practitioners, who may then refer them to sleep specialists if needed.

By Regions

By region, the market is divided into North America, Europe, APAC, and Others. Others is further divided into Middle East and South America.

North America is anticipated to maintain its position as the dominant force in the global sleep disorder market, boasting the highest share of revenue throughout the forecast period. This can be attributed to the region's advanced healthcare infrastructure, widespread awareness of the detrimental effects of sleep disorders, and the rising incidence of mental health issues stemming from sleep-related problems. For instance, more than 65% of Americans aged 20 to 59 report experiencing regular sleep difficulties. The statistics concerning sleep disorders in the USA are staggering, with 50-70 million US adults grappling with sleep disorders, 48% reporting snoring problems, 4.7% acknowledging falling asleep while driving at least once a month, and around 25 million U.S. adults dealing with obstructive sleep apnea. Furthermore, approximately 66% of patients in the USA hold a positive opinion of CPAP (Continuous Positive Airway Pressure) therapy, which aids in treating sleep disorders. These treatment options are instrumental in propelling market growth within the region.

Europe holds the second-largest share in the market due to its aging population and well-established healthcare facilities. According to the European Commission, the old-age dependency ratio, which compares the number of people aged 65 and above to those aged 15 to 64, is projected to rise from 29.6% in 2016 to 51.2% in 2070. This demographic shift is expected to exacerbate the prevalence of sleep disorders in the future.

Asia-Pacific is poised to experience the highest growth rate during the forecast period. This surge in growth can be attributed to the region's substantial population, increasing awareness of sleep disorders, evolving lifestyle preferences, and the development of healthcare infrastructure across the region.

Competitive Landscape

The sleep disorder market is characterized by an important level of competitiveness due to the presence of numerous participants. Several companies are dedicating resources to research and development, as well as introducing innovative therapeutic and diagnostic solutions for sleep disorders, with the aim of securing a substantial foothold in the competitive landscape. Additionally, some firms are engaging in strategic partnerships, joint ventures, and merger and acquisition activities to extend their market reach, enhance their brand recognition, and diversify their product offerings across different geographical regions. Some of the key players in the global marketplace are Merck & Co. Inc., Idorsia Pharmaceuticals, Sanofi, Pfizer, Dr. Reddy Laboratories, Eli Lilly and Company, Hikma Pharmaceuticals Plc, Jazz Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., and others.

Recent Developments in the Sleep Disorder Market

• In May 2022, Idorsia made a significant step forward by officially introducing Quviviq, a pharmaceutical solution designed to combat insomnia. Support the launch and ensure widespread availability, the company assembled a formidable team of 500 sales representatives. In addition to this, they outlined comprehensive plans for an assertive direct-to-consumer (DTC) marketing campaign aimed at raising awareness and promoting the product's benefits.
• In April of the same year, Oxysleep Max Care unveiled an exclusive state-of-the-art centre dedicated exclusively to addressing sleep disorders. This innovative healthcare facility boasts a wide array of rehabilitation amenities and services. The centre’s approach is uniquely holistic, blending modern medical science with alternative healing practices. It is strategically designed to offer comprehensive solutions that not only target sleep disorders but also focus on alleviating stress and facilitating body detoxification, ensuring patients receive a well-rounded and effective approach to their healthcare needs
• In July 2020, Jazz Pharmaceuticals plc disclosed that its medication Xyway had received approval from the FDA for the treatment of cataplexy and excessive daytime sleepiness in individuals with narcolepsy aged 15 years and older. This approval by the FDA for their novel sleep disorder treatment has led to an increased demand in the market and boosted the sales of the medication, contributing to higher anticipated revenues in the future.

Table of Contents

1. Executive summary
2. MARKET INTRODUCTION
   • MARKET SCOPE
   • MARKET Definitions
3. research methodology
4. market outlook
   • Key Trends
   • GUIDELINES / REGULATIONS
   • COVID- 19 IMPACT ON GLOBAL SLEEP DISORDER MARKET
   • MARKET DYNAMICS
     • Drivers
       • Increasing awareness related to sleep disorders among the patient population
       • Rising stress levels among population
       • Change in lifestyle pattern
       • Presence of potential clinical pipeline candidates
     • Restraints
       • Lower diagnosis rate
       • Side effects of sleep disorder drugs
     • Challenges
       • Regulatory Challenges
     • PriCing Analysis
     • PORTER’S FIVE FORCE MODEL
       • Threat of new entrants
       • Threat of substitute
       • Bargaining power of suppliers
       • Bargaining power of buyers
       • Intensity of competitive rivalry

5. GLOBAL SLEEP DISORDER MARKET, By disorder, MARKET ESTIMATION AND FORECAST, 2019-2032), value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • Sleep Apnea
   • Restless Legs Syndrome
   • Insomnia
   • Narcolepsy
   • Circadian disorders
   • other
6. GLOBAL SLEEP DISORDER MARKET, BY Drug, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • Benzodiazepines
   • Nonbenzodiazepines
   • Antidepressants
7. GLOBAL SLEEP DISORDER MARKET, BY Route of Administration, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • oral
   • parenteral
   • others
8. GLOBAL SLEEP DISORDER MARKET, BY End-use, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
   • INTRODUCTION
   • MARKET SHARE ANALYSIS
   • Home care settings & individuals
   • sleep laboratories
   • hospitals
9. GLOBAL SLEEP DISORDER MARKET, REGIONAL ANALYSIS MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
   • INTRODUCTION
   • NORTH AMERICA SLEEP DISORDER MARKET
     • North America Sleep Disorder Market, By Country
       • US
       • Canada
       • Mexico
     • North America Sleep Disorder Market, By Disorder
     • North America Sleep Disorder Market, By Drug
     • North America Sleep Disorder Market, By Route of Administration
     • North America Sleep Disorder Market, By End-User
   • EUROPE SLEEP DISORDER MARKET
     • Europe Sleep Disorder Market, By Country
       • Germany
       • UK
       • France
       • Italy
       • Spain
       • Russia
       • Rest of Europe
     • Europe Sleep Disorder Market, By Disorder
     • Europe Sleep Disorder Market, By Drug
     • Europe Sleep Disorder Market, By Route of Administration
     • Europe Sleep Disorder Market, By End-User
   • ASIA PACIFIC SLEEP DISORDER MARKET
     • Asia Pacific Sleep Disorder Market, By Country
       • China
       • Japan
       • India
       • Australia
       • Singapore
       • South Korea
       • Thailand
       • Indonesia
       • Malaysia
       • Philippines
       • Rest of Asia Pacific
     • Asia-Pacific Sleep Disorder Market, By Disorder
     • Asia-Pacific Sleep Disorder Market, By Drug
     • Asia-Pacific Sleep Disorder Market, By Route of Administration
     • Asia-Pacific Sleep Disorder Market, By End-User
   • MIDDLE EAST & AFRICA SLEEP DISORDER MARKET
     • Middle East & Africa Sleep Disorder Market, By Country
       • UAE
       • Saudi Arabia
       • South Africa
       • Rest of Middle East & Africa
     • Middle East & Africa Disorder Market, By Disorder
     • Middle East & Africa Sleep Disorder Market, By Drug
     • Middle East & Africa Sleep Disorder Market, By Route of Administration
     • Middle East & Africa Sleep Disorder Market, By End-User
   • SOUTH AMERICA SLEEP DISORDER MARKET
     • South America Sleep Disorder Market, By Country
       • Brazil
       • Argentina
       • Peru
       • Rest of South America
     • South America Sleep Disorder Market, By Disorder
     • South America Sleep Disorder Market, By Drug
     • South America Sleep Disorder Market, By Route of Administration
     • South America Sleep Disorder Market, By End-User

10. GLOBAL SLEEP DISORDER MARKET, COMPETITIVE Intelligence
    • COMPETITIVE POSITIONING
    • competitor benchmarking
    • COMPETIVE QUADRANT
    • market share analysis, 2022 (%)
11. GLOBAL SLEEP DISORDER MARKET, COMPANY ANALYSIS
    • Alembic Pharmaceuticals Limited
      • Company Overview
        • Business outlook
        • Headquarter
        • Established/Incorporated
        • Headcounts/ Employee strength
      • Financial Overview
        • Sales/revenue
        • R&D expenditure
        • Business segment sales share
        • Regional sales share
      • Product Offerings
      • SWOT Analysis
      • Key Developments (Expansion/New Product Development/Agreement/Mergers & Acquisitions, Partnership/Investment/Etc.)
    • Amneal Pharmaceuticals LLC
    • Apotex Inc.
    • Arbor Pharmaceuticals Inc.
    • Aurobindo Pharma USA
    • DeVilbiss Healthcare LLC
    • Reddy’s Laboratories Ltd.
    • Eli Lilly and Company
    • Hikma Pharmaceuticals PLC
    • Jazz Pharmaceuticals, Inc.
    • Lupin Pharmaceuticals, Inc.
    • Mallinckrodt
    • MERCK & CO.
    • MYLAN N.V.
    • PFIZER
    • ResMed
    • Sanofi
    • Taj Pharmaceuticals Limited
    • TAKEDA PHARMACEUTICAL COMPANY LTD.
    • Taro Pharmaceutical Industries Ltd.
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • Viatris Inc.
    • OTHERS

*Financials and Details May Not be Included in Case of Privately Held Company

Global Sleep Disorder Market Segmentation

Sleep Disorder by Type: Market Size & Forecast 2023-2030

• Insomnia
• Sleep apnea
• Restless leg syndrome
• Narcolepsy
• Circadian rhythm disorders
• Parasomnias
• Hypersomnias

Sleep Disorder by Diagnosis Method: Market Size & Forecast 2023-2030

• Polysomnography
• Multiple sleep latency test
• Epworth sleepiness scale
• Home sleep apnea testing

Sleep Disorder by Treatment: Market Size & Forecast 2023-2030

• Medications
• Cognitive-behavioral therapy
• Lifestyle changes
• Oral appliances
• Positive airway pressure (PAP) therapy
• Surgery

Sleep Disorder by Application: Market Size & Forecast 2023-2030

• Adults
• Children
• Travelers
• Shift workers

Sleep Disorder by Product: Market Size & Forecast 2023-2030

• Therapeutics
• Diagnostics
• Devices
• Digital health

Sleep Disorder by Geography: Market Size & Forecast 2023-2030

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Major Players:

• Philips Healthcare
• ResMed Inc.
• Fisher & Paykel Healthcare
• Somnomed Limited
• Inspire Medical Systems
• Koninklijke DSM N.V.
• Drive DeVilbiss Healthcare
• Compumedics Limited
• Natus Medical Incorporated
• Nihon Kohden Corporation
• Braebon Medical Corporation
• Itamar Medical Ltd.
• Sleep Number Corporation
• BMC Medical Co., Ltd.
• Cadwell Industries, Inc.
• Circadiance
• NightBalance B.V.
• Hocoma AG
• Medtronic plc
• Cardinal Health, Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sanofi
• GlaxoSmithKline plc